Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-004489-85
    Sponsor's Protocol Code Number:MORAb-009-201
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-05-14
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2014-004489-85
    A.3Full title of the trial
    A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma
    Studio randomizzato, in doppio cieco, controllato con placebo sulla sicurezza e l’efficacia di amatuximab in combinazione con pemetrexed e cisplatino in soggetti con mesotelioma pleurico maligno non resecabile.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma
    Studio randomizzato, in doppio cieco, controllato con placebo sulla sicurezza e l’efficacia di amatuximab in combinazione con pemetrexed e cisplatino in soggetti con mesotelioma pleurico maligno non resecabile.
    A.4.1Sponsor's protocol code numberMORAb-009-201
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMorphotek Inc
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMorphotek Inc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationEisai Europe Ltd
    B.5.2Functional name of contact pointMedical Information
    B.5.3 Address:
    B.5.3.1Street AddressMosquito Way
    B.5.3.2Town/ cityHatfield
    B.5.3.3Post codeAL10 9SN
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+442086001400
    B.5.5Fax number+442086001401
    B.5.6E-mailLMedinfo@eisai.net
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/13/1222
    D.3 Description of the IMP
    D.3.1Product nameChimeric Antibody to Mesothelin
    D.3.2Product code MORAb-009
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAmatuximab
    D.3.9.1CAS number 931402-35-6
    D.3.9.2Current sponsor codeMORAb-009
    D.3.9.3Other descriptive nameAMATUXIMAB
    D.3.9.4EV Substance CodeSUB128913
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product Yes
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Advanced pleural mesothelioma
    Mesotelioma pleurico avanzato
    E.1.1.1Medical condition in easily understood language
    mesothelioma
    Mesotelioma
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level LLT
    E.1.2Classification code 10035605
    E.1.2Term Pleural mesothelioma malignant advanced
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to demonstrate whether weekly amatuximab, 5 mg/kg, in combination with pemetrexed and cisplatin, has superior overall survival (OS) compared with pemetrexed and cisplatin and placebo in subjects with unresectable malignant pleural mesothelioma (MPM.
    L’obiettivo primario dello studio è dimostrare se la somministrazione settimanale di amatuximab, alla dose di 5 mg/kg, in combinazione con pemetrexed e cisplatino, presenta una sopravvivenza complessiva (overall survival, OS) superiore rispetto a pemetrexed con cisplatino e placebo in soggetti con mesotelioma pleurico maligno (MPM) non resecabile.
    E.2.2Secondary objectives of the trial
    The secondary objectives of the study are:
     To compare the treatment arms (amatuximab versus placebo) with regard to the following:
    - Progression-free survival (PFS)
    - Antitumor activity, as assessed by objective tumor response (objective response rate [ORR])
    using the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria
    - Duration of response (DR)
    - Disease control rates (DCR)
    - Duration of disease control (DDC)
    - Health related quality of life (QOL)
    - Duration of Performance Status (Eastern Cooperative Oncology Group [ECOG];
    Maintenance (DPSM)
     To evaluate the safety and tolerability of amatuximab when administered with pemetrexed and
    cisplatin
     To evaluate the relationship of amatuximab exposure to efficacy and hypersensitivity adverse
    events (AEs)
    •Confrontare i bracci di trattamento (amatuximab rispetto a placebo) sui seguenti aspetti: Sopravvivenza libera da progressione (PFS); Attività antitumorale, definita dalla risposta tumorale obiettiva (tasso di risposta obiettiva ORR]) in base ai Criteri di valutazione della risposta nei tumori solidi (RECIST) modificati; Durata della risposta (DR); Tassi di controllo della malattia (DCR); Durata del controllo della malattia (DDC); Qualità della vita (QOL) correlata alla salute; Mantenimento della durata dello stato di validità (DPSM) del Gruppo orientale di oncologia cooperativa (Eastern Cooperative Oncology Group Performance Status, ECOG)
    •Valutare la sicurezza e la tollerabilità di amatuximab quando somministrato insieme a pemetrexed e cisplatino
    •Valutare la relazione tra esposizione ad amatuximab ed efficacia ed eventi avversi (EA) da ipersensibilità
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Are at least 18 years of age at the time of informed consent
    2. Have confirmed diagnosis of MPM with the following characteristics:
    - Unresectable disease (defined as the subject not being a candidate for curative surgery)
    - Epithelial type
    - Have an archived tissue sample to be submitted either as a formalin fixed paraffin embedded (FFPE) tumor block, or 5 to 15 unstained slides
    3. Have measurable disease at Screening by computed tomography (CT) (or magnetic resonance imaging [MRI]) as defined by at least 1 lesion of ≥1.5 cm in the longest diameter for a non-lymph node or ≥1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to the modified RECIST criteria (Byrne and Nowak, 2004) (Appendix 4)
    4. Have other significant medical conditions well-controlled and stable in the opinion of the investigator for at least 30 days prior to Day 1
    5. Have an ECOG Performance Status 0 or 1 at Screening (Appendix 2)
    6. Have a life expectancy of at least 3 months, as estimated by the investigator
    7. Have adequate organ reserve as determined by laboratory test results obtained within 2 weeks prior to Study Day 1 as indicated below:
    - Absolute neutrophil count ≥1.5 × 10^9/L
    - Platelet count ≥100 × 10^9/L
    - Hemoglobin ≥9 g/dL
    - Serum bilirubin ≤1.5 × upper limit of normal (ULN) (Subjects with serum bilirubin abnormalities greater than this specified limit are eligible only if they have known Gilberts disease.)
    - Aspartate aminotransferase ≤3 × ULN
    - Alanine aminotransferase ≤3 × ULN
    - Alkaline phosphatase ≤3 × ULN
    8. Have a calculated serum creatinine clearance ≥45 mL/min using the Cockcroft-Gault equation
    9. Subjects of childbearing potential must be surgically sterile or consent to use a medically acceptable method of contraception throughout the study period. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing). If a patient of childbearing potential is neither surgically sterile nor postmenopausal, highly effective contraceptive measures must start either prior to or at Screening and continue throughout the entire study period and for at least 6 months after the last dose of chemotherapy and at least 30 days after the last dose of Test Article (amatuximab or placebo) is administered (whichever is later). A highly effective method of contraception is defined as one that results in a low failure rate (ie, less than 1% per year) when used consistently and correctly. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Women of childbearing potential must also refrain from egg cell donation for 6 months after the final dose of investigational product.
    10. Male subjects must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (ie, not of childbearing potential or practicing highly effective contraception throughout the study period and for 6 months after discontinuation of chemotherapy and for 5 weeks after Test Article (amatuximab or placebo) discontinuation (whichever is later). No sperm donation is allowed during the study period and for 90 days after Test Article discontinuation.
    11. Be willing and able to provide written informed consent
    12. Be willing and able to comply with all aspects of the protocol
    1. Avere almeno 18 anni di età al momento del consenso informato.
    2. Avere una diagnosi confermata di MPM con le seguenti caratteristiche:
    - malattia non resecabile (definita dalla non candidabilità del soggetto ad intervento chirurgico curativo)
    - tipo epiteliale
    - disponibilità di un campione di tessuto tumorale di archivio, sotto forma di blocchetto fissato in formalina e incluso in paraffina (formalin fixed paraffin-embedded, FFPE), oppure di 5-15 vetrini non colorati
    3. Avere allo screening una malattia misurabile alla tomografia computerizzata (TC) (oppure alla risonanza magnetica [RM]), definita dalla presenza di almeno 1 lesione non linfonodale di ≥1,5 cm al diametro maggiore oppure 1 linfonodo con asse corto ≥1,5 cm e misurabile in serie secondo i criteri RECIST modificati
    4. Avere altre patologie di rilievo ben controllate e stabili a giudizio dello sperimentatore da almeno 30 giorni prima del Giorno 1
    5. Avere uno stato di validità ECOG 0 o 1 allo screening
    6. Avere un’aspettativa di vita di almeno 3 mesi, a giudizio dello Sperimentatore
    7. Avere un’adeguata funzionalità degli organi definita da risultati delle analisi di laboratorio ottenuti non più di 2 settimane prima del Giorno 1 come indicato sotto:
    - conta assoluta dei neutrofili ≥1,5 x 109/l
    - conta piastrinica ≥100 × 109/l
    - emoglobina ≥9 g/dl
    - bilirubina sierica ≤1,5 × limite superiore della norma (upper limit of normal, ULN) (I soggetti con valori anomali di bilirubina sierica superiori al limite specificato sono idonei allo studio solo se affetti da sindrome di Gilbert.)
    - aspartato aminotransferasi ≤3 × ULN
    - alanina aminotransferasi ≤3 × ULN
    - fosfatasi alcalina ≤3 × ULN
    8. Avere una clearance della creatinina sierica ≥45 ml/min calcolata mediante la formula di Cockcroft-Gault
    9. I soggetti fertili dovranno essere chirurgicamente sterili oppure acconsentire all’adozione di un metodo contraccettivo accettabile dal punto di vista medico per l’intero periodo dello studio. Tutte le donne saranno considerate fertili salvo che siano in postmenopausa (amenorroiche da almeno 12 mesi consecutivi, nella fascia di età appropriata, e in assenza di altra causa nota o sospetta) o siano state sterilizzate chirurgicamente (ovvero, sottoposte a legatura bilaterale delle tube, isterectomia totale od ovariectomia bilaterale, tutto con intervento chirurgico almeno 1 mese prima della somministrazione). Se una paziente fertile non è chirurgicamente sterile né in postmenopausa, l’adozione delle misure contraccettive altamente efficaci dovrà iniziare prima o al momento dello screening e continuare per l’intera durata dello studio e per almeno 6 mesi dopo l’ultima dose di chemioterapia e almeno 30 giorni dopo la somministrazione dell’ultima dose di prodotto sperimentale (amatuximab o placebo) (a seconda di quale si verifichi dopo). Un metodo contraccettivo molto efficace è definito come quello che si traduce in un basso tasso di fallimento (ad esempio, meno dell’1% l’anno), quando utilizzato in modo coerente e corretto. L’astinenza periodica, il metodo del ritmo e il metodo del coito interrotto non sono metodi contraccettivi accettabili. Le donne in età fertile devono astenersi dalla donazione di ovociti per 6 mesi dopo l’ultima dose di prodotto sperimentale.
    10. I soggetti di sesso maschile devono essersi sottoposti a un intervento di vasectomia riuscito (azoospermia confermata) oppure devono, insieme alla compagna, soddisfare i criteri sopra descritti (ovvero, non essere fertili oppure adottare una contraccezione altamente efficace per l’intero periodo dello studio e per 6 mesi dopo l’interruzione della chemioterapia e per 5 settimane dopo la sospensione del prodotto sperimentale (amatuximab o placebo) (a seconda di quale si verifichi dopo). Non è consentita la donazione di sperma durante il periodo dello studio e per 90 giorni dopo la sospensione del prodotto sperimentale.
    11. Disponibilità e capacità di fornire un consenso informato scritto
    12. Disponibilità e capacità di agire in conformità a tutti gli aspetti del protocollo
    E.4Principal exclusion criteria
    1. Have any history of the following:
    - Prior systemic therapy or radiotherapy for MPM; local radiotherapy of noncurative intent (ie, for prevention of instrument-tract recurrence [National Comprehensive Cancer Network, 2014] and/or symptom control) is permitted
    - Evidence of other active, invasive malignancy requiring treatment within the past 5 years; noninvasive cancer history (such as carcinoma-in-situ [CIS] that has been resected) is allowed
    2. Currently have mesothelioma of the sarcomatous type, mixed histologic disease, or have malignant peritoneal mesothelioma
    3. Have confirmed presence of central nervous system metastases
    4. Active viral hepatitis or active human immunodeficiency virus infection
    5. Have evidence of any other serious systemic disease, including active bacterial or fungal infection, or any medical condition that, in the opinion of the investigator(s) could affect the subject’s safety or interfere with the study assessments
    6. Clinically significant heart disease (eg, congestive heart failure of New York Heart Association Class 3 or 4, angina not well controlled by medication, or myocardial infarction within 6 months)
    7. Electrocardiogram (ECG) demonstrating clinically significant arrhythmias (Note: subjects with chronic atrial arrhythmia, ie, atrial fibrillation or paroxysmal supraventricular tachycardia, are eligible). A clinically significant ECG abnormality, including a marked prolonged QT/QTc interval (eg, a repeated demonstration of a QTc interval of >500 ms).
    8. Have known intolerance to the Test Article (ie, documented hypersensitivity AE to prior monoclonal antibody therapy, or to amatuximab or any of its excipients)
    9. Pregnant and/or lactating females are excluded; a negative beta-human chorionic gonadotropin [ß-hCG]) is required during Screening, and a separate local assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of Test Article
    10. Have any medical or other condition that in the opinion of the investigator(s) would preclude the subject’s participation in a clinical study
    11. Are scheduled for debulking surgery during the study
    12. Are currently enrolled in another clinical study or used any investigational drug or device within 30 days (or 5 x the half-life of the investigational drug/device, whichever is longer) preceding informed consent
    1. Avere un'anamnesi tra le seguenti:
    - pregressa terapia sistemica o radioterapia per MPM; è consentita la radioterapia locale con intento non curativo (ovvero, per la prevenzione di recidive da strumentario e/o il controllo dei sintomi)
    - evidenza di altre neoplasie invasive in fase attiva che abbiano richiesto un trattamento negli ultimi 5 anni; l’anamnesi di carcinoma non invasivo (come carcinoma in situ [CIS] che sia stato asportato) è consentita
    2. Avere in atto un mesotelioma di tipo sarcomatoso, a istologia mista o un mesotelioma peritoneale maligno
    3. Avere metastasi confermate al sistema nervoso centrale
    4. Epatite virale in fase attiva o infezione da virus dell’immunodeficienza umana in fase attiva
    5. Presentare evidenze di qualsiasi altra malattia sistemica grave, come infezioni di origine batterica o fungina in fase attiva, o qualsiasi altra condizione medica che, a giudizio dello/ sperimentatore/degli sperimentatori, potrebbe avere ripercussioni negative sulla sicurezza del soggetto o interferire con le valutazioni dello studio
    6. Malattia cardiaca clinicamente significativa (ad es., scompenso cardiaco congestizio di classe 3 o 4 secondo la New York Heart Association, angina non controllata sufficientemente dai farmaci o infarto miocardico negli ultimi 6 mesi)
    7. Esame elettrocardiografico (ECG) che evidenzi la presenza di aritmie clinicamente significative (nota: i soggetti con aritmia atriale cronica, ovvero, fibrillazione atriale o tachicardia sopraventricolare parossistica, sono considerati idonei). Anomalie ECG clinicamente significative, come un marcato prolungamento dell’intervallo QT/QTc (ad es., evidenze ripetute di un intervallo QTc >500 ms).
    8. Intolleranza nota al prodotto sperimentale (ovvero, EA documentati di ipersensibilità a precedenti terapie con anticorpi monoclonali, oppure ad amatuximab o ad uno qualsiasi dei suoi eccipienti)
    9. Donne in gravidanza e/o in allattamento; è richiesta una beta-gonadotropina corionica umana negativa (ß-hCG) durante lo screening ed è richiesta una valutazione locale separata se è stato ottenuto un test di gravidanza negativo più di 72 ore prima della prima dose di prodotto sperimentale.
    10. Qualsiasi condizione medica o di altro tipo che a giudizio dello sperimentatore/degli sperimentatori precluderebbe la partecipazione del soggetto a uno studio clinico
    11. Pazienti che hanno in programma una citoriduzione chirurgica durante lo studio
    12. Pazienti attualmente arruolati in altro studio clinico o che abbiano fatto uso di un qualsiasi farmaco o dispositivo sperimentale negli ultimi 30 giorni (o per l’emivita del farmaco/dispositivo sperimentale x 5, a seconda del periodo più lungo), prima del consenso informato
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint for this study is overall survival
    L’end point primario di efficacia è costituito dalla sopravvivenza complessiva (overall survival – OS).
    E.5.1.1Timepoint(s) of evaluation of this end point
    OS is defined as the time from the date of randomization to the date of death, regardless of cause.
    L’OS è definita come il tempo trascorso dalla data della randomizzazione alla data del decesso, indipendentemente dalla causa.
    E.5.2Secondary end point(s)
    Secondary efficacy endpoints:
    PFS, ORR, DR, DCR, DDC, DPSM, and QOL (as assessed by the Lung Cancer Symptom Scale for mesothelioma)

    Exploratory endpoints:
    ORR by using the RECIST 1.1 criteria and a potential predictive biomarker.
    Sopravvivenza libera da progressione (Progression-Free Survival, PFS), tasso di risposta obiettiva (objective response rate, ORR), durata della risposta (DR), Tassi di controllo della malattia (disease control rates, DCR), Durata del controllo della malattia (duration of disease control, DDC), il mantenimento della durata dello stato di validità (Duration of Performance Status Maintenance, DPSM) e la Qualità della vita (quality of life, QOL) correlata alla salute (come valutata dalla Lung Cancer Symptom Scale per il mesotelioma)
    Obiettivi esplorativi: ORR, in base ai criteri RECIST 1.1. e individuare un potenziale biomarcatore con valore predittivo
    E.5.2.1Timepoint(s) of evaluation of this end point
    PFS: time (in weeks) from date of randomization to date of first observation of tumor progression as determined by independent radiologic assessment using the modified RECIST criteria or to date of death due to any cause, whichever comes first.
    ORR: proportion of subjects with CR/PR as defined by the modified RECIST criteria using independent radiologic review of CT/MRI scan. ORR will be assessed within 14 days after Day8 of Cycles 2, 4, &6 during the Combination Treatment Phase, within 14 days after Day8 of every 3rd cycle during Maintenance Treatment Phase, and at EOT Visit.
    DR: time from first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or to death on study (ie, death within 30 days after last dose of Test Article).
    La PFS è definita come il tempo (in settimane) trascorso dalla data della randomizzazione alla data della prima osservazione di progressione determinata da una valutazione radiologica indipendente su criteri RECIST modificati o alla data del decesso (indipendentemente dalla causa), quale che si verifichi per primo. L’ORR: come definita dai criteri RECIST modificati tramite referto radiologico. Valutata entro 14 giorni dal G8 dei cicli 2,4 e 6 durante la fase di trattamento combinato, entro 14 giorni dal G8 di ogni terzo ciclo durante la fase di mantenimento, e alla visita EOT. La DR: tempo trascorso dalla prima risposta tumorale obiettiva alla prima progressione tumorale obiettiva o al decesso nel corso dello studio (fino a 30G dopo la somm. dell’ultima dose del prodotto sperimentale).
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned13
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA55
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    France
    Germany
    Italy
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Following the end of treatment visit, subjects will be contacted by phone monthly for the next 7 months then every other month until death or the end of the study to record survival status.
    Dopo la fine delle visite di trattamento, i soggetti saranno contattati telefonicamente mensilmente per i successivi 7 mesi, poi ogni mese fino alla morte o alla fine dello studio per registrare lo stato di sopravvivenza.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.1.1Number of subjects for this age range: 0
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.2.1Number of subjects for this age range: 0
    F.1.1.3Newborns (0-27 days) No
    F.1.1.3.1Number of subjects for this age range: 0
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.4.1Number of subjects for this age range: 0
    F.1.1.5Children (2-11years) No
    F.1.1.5.1Number of subjects for this age range: 0
    F.1.1.6Adolescents (12-17 years) No
    F.1.1.6.1Number of subjects for this age range: 0
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 280
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 280
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state93
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 280
    F.4.2.2In the whole clinical trial 560
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    It is not different from the expected normal treatment of that condition
    Nulla di diverso dal normale trattamento previsto per le loro condizioni
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-05-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-07-22
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-11-30
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 18:47:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA